e-ISSN:2319-9865
p-ISSN:2322-0104

Research & Reviews: Journal of Medical and Health Sciences

Tau Protein and its Phosphorylation: Alzheimer's Disease

Sunil Kumar Singh[1*], Nisha Dhama[2], Arif Khan[1], Gaurav Singh[3]
[1]Department of Biosciences and Technology, VIT University, Vellore, Tamil Nadu, India
[2]Department of Biotechnology, Meerut Institute of Engineering & Technology, Meerut, U.P, India
[3]Department of Bioinformatics, IIIT University, Hyderabad, Telangana State, India

Review Article

Received date: 20/03/2015
Accepted date: 23/04/2015
Published date: 28/04/2015

***For Correspondence**

Sunil Kumar Singh, Department of Biosciences and Technology, VIT University, Vellore, Tamil Nadu, India, Tel: +91 9966661052

E-mail: singhsunil.kumar2012@vit.ac.in

KEYWORDS: Hyperphosphorylation; Down's syndrome; Alzheimer's disease

ABSTRACT

The alterations of insulin signaling, calcium signaling, mitochondrial deterioration and oxidative strain have been associated in the hyperphosphorylation of tau protein found in Downs syndrome dementia. Such sorts of pathogenic etiologies have clear ramifications in the counteractive action and treatment of Down's disorder (DS) dementia. The event of methylation abandons in DS is examined yet despite the fact that dubious, later studies do show criticalness. Kinases, for example, DYK1A and GlcNAcylation are examined and a Cdk5 inhibitory peptide (CIP). Indeed, even rest drug has been shown in that seniors, who have better rest, endure less subjective decay than those with slumber issues with upgraded leeway of β amyloid and tau neurofibrillary tangles. Studies have reported a high rate of slumber issues in Down's. Ecological poison arsenite and low dosage methyl mercury have been conjectured to prompt tau phosphorylation. Dietary changes to low glycemic carb and gluten shirking ought to be made. Including B vitamins may be similarly critical to avert cerebrum decay particularly in those with MTHFR and MTRR quality deformities. The remedial system of diminishing insulin resistance by up regulation of PPARS alpha with glitazones and diminishing calcium inundation into the mitochondria is said. Shielding mitochondrial decrease from oxidative anxiety with cancer prevention agents, and treatment with CBD, polyphenols, ellagic corrosive, resveratrol and other grape bioflavinoids and moderate attractive fields is examined.

INTRODUCTION

Tau is a association of microtubules- related proteins found in neurofibrillary tangles (NFT) in Alzheimer's ailment (AD) mind. Found 39 years prior, as a heat stable protein that encourages the microtubule get together by Weingarten, Cleveland and partners showed that tau is a phosphoprotein which by phosphorylation, adversely controls its capacity to empower microtubule gathering in 1977 [1]. Iqbal and Grundke in 1986 found that tau was hyperphosphorylated in mind excerpts from AD cases and that it may bring about the imperfection in microtubule get together and self-gathering into matched helical fibers, framing neurofibrillary tangles [2-6].

Tau phosphorylation occasions are likely successive and as per Johnson and Stoothoff and the capacity for of tau to self-partner may be created by an unevenness in the movement pf particular protein kinases or phosphatases (Phases) [7].

Tau is unusually phosphorylated in a gathering of uncommon autosomal degenerative illness known as front transient dementia with Parkinson's brought about by a change of the tau quality situated on chromosome 17q21. Different tauopathies incorporate dynamic supranuclear paralysis, unending traumatic encephalopathy, Lytico-Bodig ailment (Parkinson-dementia complex of Guam), a tangle-transcendent dementia, with NFTs like AD, yet without plaques. Ganglioglioma and gangliocytoma,

meningioangiomatosis, subacutesclerosingpan encephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz sickness, and lipofuscinosis are likewise recorded as tauopathies. Pick complex issue have been proposed by Kertesz as a range of presentations of the same issue in light of their pathology. In these tauopathies, the neurofibrillary changes are comprised of strangely hyperphosphorylated tau, hence exceptionally recommending that this anomaly causes their dementia and marked this, the neurotoxic condition of tau. The creators recommend that the hindrance of strange hyperphosphorylation of tau offers a promising focus for treatment [8-16].

A late study by Jellinger's gathering amid the late 11th International Conference on Alzheimer's and Parkinson's Disease in Florence Italy on Tau pathology uncovered that neurons encompassed by perineuronal nets containing aggregan appear to be secured against tau pathology and therefore poisonous quality may be turned away by perineuronal nets. These nets comprise of contrarily charged, sugary proteins called chondroitin sulfate proteoglycans (CSPGs). The nets frame an enclosure around neurons [17]. There is a harmony between a fine regulation of axonal and dendritic development so that grown-up CNS can save imperative associations while as yet taking into consideration basic pliancy and help to settle neural connections and protect recollections and grows as discriminating periods end, anticipating further versatility [18-20].

Current Dogma is that AD movement starts with amyloid beta removal in the entnorinal cortex before tau pathology. A late study by Heiko Braak at Goethe University, Frankfurt, Germany, provide reason to feel ambiguous about this arrangement by resuscitating an old level headed discussion about whether tau pathology comes prior. This new work discovered pretangle tau stores in the brainstem of the greater part of individuals under 30 [21]. This has now driven a few analysts to propose that the ailment begins ahead of schedule in life, with tau pathology in the brainstem. Therefore early anticipation of tau hyperphosphorylation may be instrumental than any treatment after dementia is diagnosed [22].

Down's disorder dementia with hyperphosphorylation of tau has been thought to be because of the quality encoding the minibrain kinase/ double specificity tyrosine phosphorylated and controlled kinase 1A (DYRK1A). This gene is situated in the Down's disorder (DS) basic locale of chromosome 21, which is tripled in Downs [23]. Studies by Weigle and collegues demonstrate that DYRK1A phosphorylates tau protein, and since this kinase is likewise included in tau protein phosphorylation, it adds to neurofibrillary degeneration, and may be upgraded in patients with DS. A later study by Weigle onDYRK1A overexpression in DS brains is that it may add to right on time onset neurofibrillary degeneration straightforwardly through hyperphosphorylation of tau and by implication through phosphorylation of option joining element, prompting an unevenness between 3R-tau and 4R-tau [24-28].

Presently it isn't simply Downs' syndrome, where the cerebrum tau is three to four hyperphosphorylated. The irregularly hyperphosphorylated tau ties to ordinary tau rather than the tubulin and this coupling prompts the development of tau oligomers. As per the Igbal group, the anomalous hyperphosphorylated tau is fit for sequestering typical tau as well as MAP MAP1 and MAP2 and bringing about disturbance of the microtubule system advanced by these proteins. Weigle et al. notice the O-GlcN Acylation of tau in their article which brings the idea of this rich, dynamic and inducible post-transitional change [29].

Like phosphorylation, O-GlcNAcylation (or essentially GlcNAcylation) is sometimes, happening at the same or nearby destinations, regulating one another. GlcNAcylation influences protein-protein cooperations, action, dependability, and outflow. GlcNAcylation of proteins inside the insulin flagging pathway and adds to insulin resistance and aides clarify the increment of Alzheimer's occurrence among diabetics [30]. Dias and Hart at Johns Hopkins reported that hypoglycemia inside the mind may lessen the typical GlcNAcylation of tau, uncovering kinase acceptor destinations, hence prompting hyperphosphorylation, which prompts tangle development and neuronal demise [31-34].

The most widely recognized hereditary reason for mental impediment is Down's disorder and the qualities included in homocysteine/folate digestion system assumes a part in the etiology of this issue. The attentions of the metabolites identified with the methylation cycle in the blood of 35 youthful people with DS and 47 controls of tantamount age was tried by Obeid and partners in Homburg Germany [35]. They connected a scientific model to take in more about the regulation of the methylation cycle in DS Concentrations of cystathionine, cysteine, betaine, choline, dimethyl glycine, holotranscobalamin, S-adenosylhomocysteine (SAH), S-adenosyl methionine (SAM), were fundamentally higher in DS contrasted with the controls. They reasoned that abundance of cystathionine beta synthase (CBS) movement, increments in the exercises of methionine synthase and betadine homocysteine methyl transferase, and in methionine info [36-40].

A late study by Jellinger's gathering amid the late 11th International Conference on Alzheimer's and Parkinson's Disease in Florence Italy on Tau pathology uncovered that neurons encompassed by perineuronal nets containing aggregan appear to be ensured against tau pathology and subsequently harmfulness may be turned away by perineuronal nets [41]. These nets comprise of contrarily charged, sugary proteins called chondroitin sulfate proteoglycans (CSPGs). The nets shape a pen around neurons. There is a harmony between a fine regulation of axonal and dendritic development so that grown-up CNS can safeguard vital associations while as yet taking into account basic pliancy and help to balance out neurotransmitters and protect recollections and grows as discriminating periods end, forestalling further versatility [12, 42].

Current dogma is that AD movement starts with amyloid beta testimony in the entnorinal cortex before tau pathology. A

late study by HeikoBraak at Goethe University, Frankfurt, Germany, give occasion to feel qualms about this grouping by restoring an old verbal confrontation about whether tau pathology comes prior [43]. This new work discovered pretangle tau stores in the brainstem of the lion's share of individuals under 30. This has now driven a few scientists to propose that the sickness begins right on time in life, with tau pathology in the brainstem. In this manner early counteractive action of tau hyperphosphorylation may be instrumental than any treatment after dementia is diagnosed [44-48].

It is a piece of the idea of INSTAND to offer examples for examination with information in a clinically important reach, which permits additionally the reference rangeâ€" related assessment and for the joined arrangement of information of these parameters translations applicable for differential finding of dementia and different maladies of the sensory system [49]. This methodology speaks to an additionally requesting quality appraisal contrasted with a sole confirmation of numerical qualities. This interest of a general quality appraisal drove us to the augmentation of the overview, byrequesting the research facilities own cut off qualities, their choice base for distinguishing proof of a typical versus an obsessive worth [50]. Moreover by different decision questions we offered the opportunity to enhance the learning base in the single lab for differential indicative translations. By this idea we got a solid depiction of the truth of the everyday scientific practice in diverse labs, not quite the same as master overviews with controlled, basic preanalytical and logical conventions. Because of the late advancement of methods for test adjustment we could keep away from in the overview for dispersion of tests the regular preanalytical issue [51-53].

The investigation of these marker proteins is an investigative as well as a financial issue. Just gradually, with enhanced information of the neurologists and therapists, the sign for the appeal of this examination was enhanced, as an essential commitment to cost diminishment in the research centres for these generally lavish examines of distinctive parameters with diverse importance and qualities [54-60].

DISCUSSION

A skin biopsy was taken from a specimen of subjects with comparative demographic qualities. When we analysed the gathering of AD, this displayed fundamentally more elevated amounts of p-Tau (AT8: hyperphosphorylated at Ser 202) than both control and non-degenerative dementia bunch [61-63]. These antibodies were picked in light of the fact that in human studies, Ser396 phosphorylation (PHF) has been accounted for as an occasion that begins right on time in neurodegeneration and increments with maturing and with the infection progress. Phosphorylation at Ser202 then again is constantly present and fundamentally expanded in infected brains when contrasted with controls [64].

These destinations have likewise been accounted for in the reversible tau hyperphosphorylation that happens in sleeping creatures proposed as a model for the investigation of taupathies. In this model both locales (S396 and S202) present an essential increment. We affirm here by method for Western smear the vicinity of p-Tau in the skin demonstrating a comparative atomic weight as in different organs. The vicinity of p-Tau in the skin gives accordingly pertinent data, and in our model AT8 (S202) immunoreactivity was fundamentally connected with the vicinity of AD [65].

The skin opens fascinating potential outcomes for the investigation of neurodegenerative illnesses on the grounds that it is exceedingly innervated and has the limit of creating and discharging a few neuropeptides [66]. It likewise communicates qualities included in neurological infections like APP, Tau, PSEN1 and PARK2 among others. As indicated by this, few sicknesses from the sensory system have dermal appearances, as it is the situation of PD, where there is an expanded danger of melanoma and patients present seborrhea and hyperhidrosis other than the established engine signs of the ailment [67].

In addition to becoming accumulated, Tau and different proteins that partake in neurodegenerative maladies translocate inside the cell core and connect with DNA [68]. Current confirmation maintenances that Tau partakes in anxiety reaction ensuring DNA, advances chromosome dependability by method for its association with both microtubules and chromatin, and upon DNA tying permits representation of quiet qualities drenched in heterochromatin [69]. These epigenetic changes on the other hand, are viewed as a wellspring of neurodegeneration advanced by Tau, since it prompts the interpretation of distorted qualities in neurons. It is then of extraordinary interest that skin biopsies give the likelihood to investigate Tau conduct in connection with epigenetic changes [70].

Biomarkers of neurodegenerative infections have been produced as of late, primarily in view of cutting edge sub-atomic neuroimaging. Most wellbeing frameworks on the planet, in any case, can't manage the cost of these studies for the clinical practice. Thusly, skin biopsies speak to a different option for backing the finding of the two most critical neurodegenerative maladies, by applying immunohistochemistry with monetarily accessible antibodies. This could be possible in a standard pathology lab of overall healing centers and clinical research facilities [71].

In this review study including CSF profiles of subjects clinically diagnosed with AD or iNPH, we discovered the p-tau focuses to be fundamentally lower in iNPH recommending diverse CSF profiles between the two gatherings. In spite of the fact that the p-tau is lower in iNPH in univariate investigation, the perception is less obvious in multivariate examination. MMSE scores, training, Aβ42, absolute tau, and ATI demonstrated no critical contrasts [72].

Former studies have explored the utilization of CSF as an intends to separate AD from different dementias. They have demonstrated that CSF profiles can separate AD from FTD, LBD, and Creutzfeldt-Jakob malady (CJD). In one study, utilizing a t-tau by Aβ42 plot, it was conceivable to segregate AD and non-AD regions of the plot, coming about with 92% of the AD subjects inside

the AD range [71]. It was likewise reported that tau was a compelling biomarker for CJD; its affectability and specificity was 94% and 90%, separately, with a positive prescient estimation of 92%. P-tau additionally demonstrated an affectability of 72% and specificity of 93% when used to separate early-onset AD and FTD. These studies demonstrate that investigating CSF profiles can be a capable way to deal with separating dementias [71-73].

The normal aggregate protein fixations for the AD and NPH gathering were 42.57 mg/dL and 53.25 mg/dL, separately. The normal aggregate protein levels of the two gatherings fall under the ordinary reach for sound people, which go from 15-60 mg/dL [73].

It has been recommended that breaking down CSF may turn into a powerful system in separating NPH and AD. Further studies with bigger specimen sizes are obliged to survey the estimation of biomarkers when used to separate in the middle of AD and NPH. The discoveries in this study may manage others to better study the employments of CSF investigation as an apparatus in the conclusion of iNPH [74,75].

CONCLUSION

Tau hyperphosphorylation found in Down's dementia and Alzheimer's and different tauopathies has been exhibited with changes of insulin signaling, calcium signaling, mitochondrial decline and oxidative stress. The event of methylation imperfections in DS and kinases, for example, DYK1A and GlcNAcylation over declaration and also a Cdk5 inhibitory peptide (CIP) concealment of tau hyperphosphorylation has been recorded. Methylation abandons in MTHFR and MTRR qualities have additionally been talked about.

Aversion of tau hyperphosphorylation in Downs' disorder with slumber prescription is suggested. Cleaning up the earth particularly methyl mercury and arsenate and utilizing sustenances high as a part of cell reinforcements may forestall intellectual decay. Cleaning up the eating regimen with evasion of high glycemic eating routine and gluten is similarly imperative and eating an eating regimen high in cancer prevention agents and including B vitamins due to MTHFR and MTRR quality deformities. Effective cancer prevention agents like muscadine grape seed may be particularly imperative in Down's disorder. Neuroprotectives, for example, CBD may end up being strong treatment in DS dementia and Alzheimer's. Moderate attractive treatment for moderate subjective disability alongside anti-microbials, for example, minocycline and doxycycline for spirochetal related dementia is highlighted as more proof for the rising part of pathogens in Alzheimer's infection unfolds. Pharmaceutical and biotec treatment, for example, BACE1 inhibitors are past the extent of this paper however might soon discover viability too.

The 22 cases utilized for this example were partitioned equitably between the AD and iNPH bunches. For the whole specimen, there were 9 guys and 13 females. MMSE scores and years of instruction were not fundamentally distinctive between the two gatherings. The iNPH gathering was altogether more seasoned than AD bunch. There was no critical relationship for sexual orientation and determination.

CSF p-tau which was fundamentally lower in the iNPH bunch in an unadjusted investigation. Investigations of the CSF markers utilizing the log transformed qualities demonstrated no huge contrast for any of the markers in the wake of changing for age, training, and sexual orientation. There was a backwards relationship in the middle of age and p-tau levels as p-tau levels had a tendency to increment with more youthful ages ($r = -0.48$, $p = 0.02$)

REFERENCES

1. Nichols TW , et al. Hyperphosphorylation of Tau Protein in Downâ€™s Dementia and Alzheimerâ€™s Disease: Methylation and Implications in Prevention and Therapy J Alzheimers Dis Parkinsonism. 2014; 4: 159.
2. Ildefonso RL, et al. Presence of Phosphorylated Tau Protein in the Skin of Alzheimer´s Disease Patients J Mol Biomark Diagn S. 2015; 6: 005.
3. Tsai A, et al. Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimerâ€™s Disease J Alzheimers Dis Parkinsonism. 2014; 4: 150.
4. Reiber H, et al. Neurochemical Dementia Diagnostics â€“ Interlaboratory Variation of Analysis, Reference Ranges and Interpretations J Alzheimers Dis Parkinsonism. 2014; 4: 147.
5. Shin HW, et al. Differences in BDNF Serum Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment J Psychiatry. 2015; 18: 245
6. Pasha EP, et al. Ethnoracial Disparities in Alzheimerâ€™s Disease: Target on Cardiovascular Risks via Lifestyle Changes? J Gerontol Geriat Res. 2014; 3: 128.
7. Ressner P, et al. Computer-Assisted Cognitive Rehabilitation in Stroke and Alzheimer's disease J Neurol Neurophysiol. 2014; 5: 260.
8. Park AL , et al. Is There Anything Special About Intergenerational Approaches to Older People with Dementia? A Review J Alzheimers Dis Parkinsonism. 2014; 4: 172.
9. Miyaoka T, et al. Effect of Donepezil on Sleep and Activity in Alzheimerâ€™s Disease: Actigraphic and Polysomnographic

Assessment J Alzheimers Dis Parkinsonism. 2014; 4: 157.

10. Hanby MF, et al. Emotional and Cognitive Processing Deficits in People with Parkinson â€™s Disease and Apathy J Alzheimers Dis Parkinsonism. 2014; 4: 156.
11. Camargo CHF, et al. Orthostatic Hypotension and its Relationship to the Clinical Course of Patients with Parkinsonâ€™s Disease J Alzheimers Dis Parkinsonism. 2014; 4:155.
12. Davey DA , et al. Alzheimer's Disease, Cerebrovascular Disease and Dementia: A Potentially Preventable and Modifiable Syndrome J Alzheimers Dis Parkinsonism. 2015; 5: 184.
13. Sani M, et al. Successful Regeneration of CNS Nerve Cells a Possible Bye Bye O Debilitating Effects Of Neurodegenerative Diseases J Alzheimers Dis Parkinsonism. 2015; 5: 182.
14. Stephenson D, et al. Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases J Alzheimers Dis Parkinsonism. 2015; 5: 183.
15. Devasena T and Francis a A.P , et al. Nanotoxicity-Induced Alzheimer Disease and Parkinsonism: Not Further than Diagnosis J Alzheimers Dis Parkinsonism. 2015; 5: 178.
16. Lukiw WJ, et al. Microbial Sources of Amyloid and Relevance to Amyloidogenesis and Alzheimerâ€™s Disease. 2015;
17. Jana P, et al. Epidemiology and Genetics of Alzheimerâ€™s Disease J Alzheimers Dis Parkinsonism. 2015; 5: 172.
18. Gareri P, et al. The Role of Quetiapine in the Treatment of Alzheimer's Disease J Gerontol Geriatr Res. 2015; 4: 197
19. Miller MD, et al. Preparing for the Rise in Alzheimers Disease Cases: A Proposal for Training Support Personnel J Gerontol Geriatr Res. 2015; 4: 195.
20. Kim H, et al. A Voxel-Based Morphometry Study in Alzheimerâ€™s Disease and Mild Cognitive Impairment J Psychiatry. 2015; 18: 237.
21. Ramdani L, et al. Multifunctional Curcumin-Nanocarriers Based on Host-Guest Interactions for Alzheimer Disease Diagnostic J Nanomed Nanotechnol. 2015; 6: 270
22. RodriacuteguezLeyva Ildefonso, et al. Presence of Phosphorylated Tau Protein in the Skin of Alzheimer´s Disease Patients J Mol Biomark Diagn. 2015; S6: 005
23. Lara Hvidsten, et al. Young Onset Dementia study – A Prospective Cohort Study of Quality of Life and Specific Needs in Persons with Young Onset Dementia and their Families J Clin Trials. 2015; 5: 204
24. Evan P Pasha, et al. Ethnoracial Disparities in Alzheimerâ€™s Disease: Target on Cardiovascular Risks via Lifestyle Changes? J Gerontol Geriatr Res. 2014; 3: e128
25. FelixMartin Werner and Rafael Coventildeas, et al. Might Combined GABAA Agonists and NMDA Antagonists have a Therapeutic and maybe a Prophylactic Effect in Alzheimer's and Parkinson's Disease? J Cytol Histol. 2015; 6: 298
26. Knarik Arkun, et al. Effect of Lewy Bodies on Mitochondrial DNA Copy Numbers and Deletion Burden in Parkinson's Disease Substantia nigra Neurons J Alzheimers Dis Parkinsonism. 2015; 4: 175
27. Orwa Aboud and Sue T. Griffin W, et al. Silver Staining of Alzheimer's Disease J Neurol Disord. 2014; 2: i103
28. Pavel Ressner, et al. Computer-Assisted Cognitive Rehabilitation in Stroke and Alzheimer's disease J Neurol Neurophysiol. 2014; 5: 260
29. Pranami Bhaumik, et al. A Rare Intronic Variation of Presenilin-1. 2014; 1
30. Astrid Haram, et al. Clinical Correlates of RBD in Early Parkinson Disease J Alzheimers Dis Parkinsonism. 2014; 4: 174
31. Hascalovici J and Schipper HM, et al. HemeOxygenase-1: Transducer of Sterol Dys-Regulation in Alzheimer Disease J Glycomics Lipidomics. 2014; 4: 124
32. Victoria I Bunik, et al. Benefits of Thiamin. 2014.
33. ALa Park, et al. Is There Anything Special About Intergenerational Approaches to Older People with Dementia? A Review J Alzheimers Dis Parkinsonism. 2014; 4: 172
34. Hyun Kim, et al. Differences in C-reactive Protein Level in Patients with Alzheimers Disease and Mild Cognitive Impairment J Psychiatry .2015.
35. David R. Borchelt, et al. Proteostasis and Secondary Proteinopathy in Alzheimer's Disease J Alzheimers Dis Parkinsonism. 2014; 4: 145
36. Vanessa K Hinson, et al. Forced Exercise for Freezing of Gait in Post STN DBS Parkinson's Disease Patients J Alzheimers Dis Parkinsonism. 2014; 4: 171

37. Borroni B, et al. Diagnosing Progressive Supranuclear Palsy: Role of Biological and Neuroimaging Markers J Alzheimers Dis Parkinsonism. 2014; 4: 168

38. Keiko Ikemoto, et al. Lectin-Positive Spherical Deposits.2014.

39. Xu Xin, et al. The Hopkins Verbal Learning Test and Detection of MCI and Mild Dementia: A Literature Review J Alzheimers Dis Parkinsonism. 2014; 4: 166

40. Robin Altman, et al. The Postprandial Effects of a Moderately High-Fat Meal on Lipid Profiles and Vascular Inflammation in Alzheimer's Disease Patients: A Pilot Study J Gen Pract. 2014; 2: 186

41. Paul Whitesman, et al. Preliminary Set Theory-Type Analysis of Proteins Associated With Parkinson's Disease J Alzheimers Dis Parkinsonism. 2014; 4: 170

42. Raheel Mushtaq, et al. Comparison of Cognitive Symptoms in Subtypes of Alzheimer's disease.2014.

43. Servello A, et al. Role of Cardiovascular Comorbidity and Depressive Symptoms on One-Year Clinical Progression of Alzheimer's Disease. 2014.

44. Roberta Ciuffini, et al. Visual Evoked Potentials in Alzheimer's Disease: Electrophysiological Study of the Visual Pathways and Neuropsychological Correlates J Alzheimers Dis Parkinsonism. 2014; 4: 158.

45. Carrie A Ciro, et al. Improving Daily Life Skills in People with Dementia: Testing the STOMP Intervention Model J Alzheimers Dis Parkinsonism. 2014; 4: 165.

46. Travis H Turner, et al. Epidermal Growth Factor. 2014.

47. Yellamma K, et al. Silk Protein, Sericin as a Cognitive Enhancer in Alzheimer's Disease J Alzheimers Dis Parkinsonism. 2014; 4: 163.

48. Tiwari SC and Soni RM, et al. Alzheimer's Disease Pathology and Oxidative Stress: Possible Therapeutic Options J Alzheimers Dis Parkinsonism. 2014; 4: 162.

49. Barbara Cynthia Fisher, et al. The Benefits of Cognitive Stimulation or Training/Rehabilitation upon Brain Function as an Efficacious Treatment for Diagnosed Dementia or Mild Cognitive Decline J Alzheimers Dis Parkinsonism. 2014; 4: 161.

50. Faris Yaghmoor, et al. The Role of TREM2 in Alzheimer's Disease and Other Neurological Disorders J Alzheimers Dis Parkinsonism. 2014; 4: 160.

51. Tsuyoshi Miyaoka, et al. Effect of Donepezil on Sleep and Activity in Alzheimer's Disease: Actigraphic and Polysomnographic Assessment J Alzheimers Dis Parkinsonism. 2014; 4: 157.

52. Martha F Hanby, et al. Emotional and Cognitive Processing Deficits in People with Parkinson's Disease and Apathy J Alzheimers Dis Parkinsonism. 2014; 4: 156.

53. Carlos Henrique Ferreira Camargo, et al. Orthostatic Hypotension and its Relationship to the Clinical Co urse of Patients with Parkinson's Disease J Alzheimers Dis Parkinsonism. 2014; 4: 155.

54. Junseong Park, et al. Evaluation and Identification of Protein Blood Biomarkers for Alzheimer's Disease: A Systematic Review and Integrative Analysis J Mol Biomark Diagn. 2014; 5: 190.

55. Amir Nazem, et al. Alzheimer's Disease Drug Discovery may be Misled by Wrong Animal Models J Gerontol Geriatr Res. 2014; 3: e127.

56. Joan HQ Shen, et al. Validation of an Alzheimer's Disease Assessment Battery in Asian Participants With Mild to Moderate Alzheimer's Disease J Gerontol Geriatr Res. 2014; 3: 167.

57. Mi Tian, et al. Alzheimer's Disease and Dementia, Under-Recognized Public Health Crisis in China J Gerontol Geriatr Res. 2014; 3: 179.

58. VandeWeerd C, et al. Changes in Conflict Resolution Style over Time: The Risk for Persons with Alzheimer's Dementia Aging Sci. 2014; 2: 127.

59. Xuesong Chen, et al. Role of LDL Cholesterol and Endolysosomes in Amyloidogenesis and Alzheimer's Disease J Neurol Neurophysiol. 2014; 5: 236.

60. Koji Terasawa, et al. Relevance between Alzheimer's Disease Patients and Normal Subjects Using Go/No-Go Tasks and Alzheimer Assessment Scores J Child Adolesc Behav. 2014; 2: 162.

61. James Oluwagbamigbe Fajemiroye, et al. Alzheimer's Disease and Animal Models in Retrospect Med chem. 2014; 4: 701.

62. Hiroaki Tanaka, et al. Relationship with Bipolar Temperament and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease Brain Disord Ther. 2014; 3: 144.

63. Emanuela Onofri, et al. Cognitive Performance Deficits and Dysgraphia in Alzheimer's Disease Patients J Neurol Neurophysiol. 2014; 5: 223.

64. Aryal R, et al. Is the A-beta peptide of Alzheimer's Disease an Antimicrobial Peptide? J Gerontol Geriatr Res. 2014; 3: 165.

65. Christian Barbato, et al. Alzheim.2014.

66. Shephali Bhatnagar, et al. Compatible Changes of Lead microRNAs in Circulating Plasma and Brain in Senescence-Accelerated Aging and Alzheimer's disease Mouse Models Aging Sci. 2014; 2: 125.

67. Cacabelos R, et al. The Pathogenic Component of the APOE-TOMM40 Region in Alzheimer's disease: Its Implications in Metabolomics and harmacogenomics Metabolomics.2014; 4: e129.

68. Nazem A, et al. Nanotechnology Building Blocks for Intervention with Alzheimer's Disease Pathology: Implications in Disease Modifying Strategies J Bioanal Biomed. 2014.

69. Jacques Hugon, et al. Involvement of PKR in Alzheimer's Disease J Alzheimers Dis Parkinsonism. 2014; 4: 154.

70. Garth F Hall, et al. Report from the Tau Front: Cantoblanco 2013 J Alzheimers Dis Parkinsonism. 2014; 4: e133.

71. Moretti DV, et al. Impairment of the Posterior Part of the Mirror Neurons System in Alzheimer's Disease: Evidence from EEG Biomarkers J Alzheimers Dis Parkinsonism. 2014; 4: 153.

72. Jeroen J.M. Hoozemans, et al. Increased IRAK-4 Kinase Activity in Alzheimer's Disease 2014 4 Kinase Activity in Alzheimer's Disease; IRAK-1/4 Inhibitor I Prevents Pro-inflammatory Cytokine Secretion but not the Uptake of Amyloid Beta by Primary Human Glia. J Clin Cell Immunol. 2014; 5: 243.

73. Balachandar Rakesh, et al. A Retrospective Study on Relation between Cognitive Performance and Lobar Perfusions of Brain in Alzheimer's Dementia using Single Photon Emission Computer Tomography Brain Disord Ther. 2014; 3: 135

74. Kentaro Horiuchi, et al. Rivastigimine for Relatively Younger Alzheimer's Disease Patient Brain Disord Ther. 2014; 3: 133.